US Patent No: 4,689,320

Number of patents in Portfolio can not be more than 2000

Method for inhibiting propagation of virus and anti-viral agent

1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

Described is a method for inhibiting propagation of virus which comprises delivering one or more oligodeoxynucleotides or polydeoxynucleotides to a place where a messenger RNA (mRNA) generated on propagation of the virus exists, characterized in that the oligodeoxynucleotides or polydeoxynucleotides are identical in DNA sequence with a portion of the structure of DNA hybridizable to the mRNA, the structure being capable of hybridizing to the mRNA. Also described is an anti-viral agent which comprises an effective amount of one or more oligodeoxynucleotides or polydeoxynucleotides with a conventional liquid vehicle or excipient, characterized in that the oligodeoxynucleotides or polydeoxynucleotides are identical in DNA sequence with a portion of the structure of DNA hybridizable to an mRNA generated on propagation of the virus, the structure being capable of hybridizing to the mRNA. The method and the agent can widely be applied to the treatment of viral diseases.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ISIS PHARMACEUTICALS, INC.CARLSBAD, CA963

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kaji, Akira 1-9, Daimoncho 1-chome, Higashikurume-shi, Tokyo, 203, JP 14 514

Cited Art

Patent Info (Count) # Cites Year
 
DR. KARL THOMAE GMBH (1)
4,433,140 Tridecadeoxynucleotide, process for preparation thereof, and use thereof 3 1982
 
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
4,464,359 (2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof 19 1981
 
THE JOHNS HOPKINS UNIVERSITY (1)
4,511,713 Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells 89 1982
 
WISTAR INSTITUTE, THE, A CORP. OF PA (1)
4,393,201 DNA Which codes for glycoprotein of era-strain rabies virus 15 1981

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
ISIS PHARMACEUTICALS, INC. (72)
6,310,044 Oligonucleotide therapies for modulating the effects of herpesviruses 5 1992
5,580,767 Inhibition of influenza viruses by antisense oligonucleotides 60 1992
5,514,577 Oligonucleotide therapies for modulating the effects of herpes viruses 63 1993
5,639,595 Identification of novel drugs and reagents 11 1993
7,037,646 Amine-derivatized nucleosides and oligonucleosides 3 1994
5,643,780 Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA 5 1994
5,658,891 Oligonucleotide therapies for modulating the effects of herpesviruses 25 1994
5,837,449 Compositions and methods for modulating .beta.-amyloid 9 1994
6,262,241 Compound for detecting and modulating RNA activity and gene expression 17 1995
5,852,182 Thiol-derivatized oligonucleosides 12 1995
5,872,232 2'-O-modified oligonucleotides 41 1995
5,859,221 2'-modified oligonucleotides 70 1995
5,587,469 Oligonucleotides containing N-2 substituted purines 118 1995
5,856,099 Antisense compositions and methods for modulating type I interleukin-1 receptor expression 5 1996
5,808,027 N-2 substituted purines in oligonucleotides 2 1996
6,077,833 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 16 1996
5,767,102 Antisense composition and method for treatment of CMV infection 4 1997
6,339,066 Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate .beta.I, .beta.II, .gamma., .delta., .EPSILON., .zeta. and .eta. isoforms of human protein kinase C 0 1997
5,985,558 Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos 29 1997
5,965,722 Antisense inhibition of ras gene with chimeric and alternating oligonucleotides 12 1997
5,877,309 Antisense oligonucleotides against JNK 51 1997
6,001,991 Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression 3 1997
6,005,087 2'-modified oligonucleotides 56 1998
6,528,631 Oligonucleotide-folate conjugates 20 1998
6,887,906 Compositions and methods for the delivery of oligonucleotides via the alimentary canal 28 1998
6,277,967 Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages 12 1998
6,242,589 Phosphorothioate oligonucleotides having modified internucleoside linkages 16 1998
6,232,463 Substituted purines and oligonucleotide cross-linking 4 1998
6,166,199 N-2 substituted purines 0 1998
6,221,850 Antisense oligonucleotide compositions and methods for the modulation of JNK proteins 4 1998
6,399,754 Sugar modified oligonucleotides 10 1998
6,177,246 Compositions and methods for modulating .beta.-amyloid 7 1998
6,359,124 Antisense inhibition of ras gene with chimeric and alternating oligonucleotides 11 1999
6,335,434 Nucleosidic and non-nucleosidic folate conjugates 43 1999
6,133,246 Antisense oligonucleotide compositions and methods for the modulation of JNK proteins 60 1999
6,369,209 Oligonucleotides having A-DNA form and B-DNA form conformational geometry 10 1999
8,153,602 Composition and methods for the pulmonary delivery of nucleic acids 0 1999
6,841,539 Compositions and methods for topical delivery of oligonucleotides 11 1999
6,319,906 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 10 1999
6,656,730 Oligonucleotides conjugated to protein-binding drugs 18 1999
6,326,358 Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages 14 1999
6,440,943 Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages 11 1999
6,312,900 Antisense oligonucleotide compositions and methods for the modulation of activating protein 1 3 1999
6,265,558 Thiol-derivatized nucleosides and oligonucleosides 10 1999
6,531,584 2'modified oligonucleotides 42 1999
6,653,458 Modified oligonucleotides 7 1999
6,867,294 Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages 3 1999
6,753,423 Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals 3 2000
6,762,169 Ligand-conjugated oligomeric compounds 6 2000
6,809,193 Antisense oligonucleotide compositions and methods for the modulation of JNK proteins 14 2001
6,811,975 Phosphorothioate oligonucleotides having modified internucleoside linkages 6 2001
7,056,896 Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages 1 2001
7,119,184 Oligonucleotides having A-DNA form and B-DNA form conformational geometry 0 2001
6,861,514 Nucleosidic and non-nucleosidic folate conjugates 2 2001
7,138,517 Sugar modified oligonucleotides 8 2001
6,537,973 Oligonucleotide inhibition of protein kinase C 5 2001
6,747,014 Compositions and methods for non-parenteral delivery of oligonucleotides 20 2001
7,695,902 Oligoribonucleotides and ribonucleases for cleaving RNA 3 2002
6,737,520 Oligonucleotides having A-DNA form and B-DNA form conformational geometry 0 2002
6,919,439 Derivatized oligonucleotides having improved uptake and other properties 0 2002
7,235,650 Derivatized oligonucleotides having improved uptake and other properties 0 2002
7,235,653 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 2 2003
7,812,149 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations 0 2003
8,084,432 Compositions and methods for treatment of pouchitis 0 2004
8,394,947 Positionally modified siRNA constructs 0 2004
7,960,355 Compositions and methods for the modulation of the expression of B7 protein 0 2004
RE39464 Oligonucleolotides having site specific chiral phosphorothioate internucleoside linkages 2 2004
7,884,086 Conjugates for use in hepatocyte free uptake assays 1 2005
8,377,897 Compositions and methods for non-parenteral delivery of oligonucleotides 0 2005
7,897,582 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 0 2007
8,101,585 Compositions and methods for the modulation of JNK proteins 0 2007
7,964,579 Compositions and methods for topical delivery of oligonucleotides 0 2009
 
WISCONSIN ALUMNI RESEARCH FOUNDATION (10)
5,703,055 Generation of antibodies through lipid mediated DNA delivery 173 1994
5,580,859 Delivery of exogenous DNA sequences in a mammal 460 1994
5,589,466 Induction of a protective immune response in a mammal by injecting a DNA sequence 340 1995
6,673,776 Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human 1 1995
5,693,622 Expression of exogenous polynucleotide sequences cardiac muscle of a mammal 138 1995
6,228,844 Stimulating vascular growth by administration of DNA sequences encoding VEGF 18 1997
6,710,035 Generation of an immune response to a pathogen 10 1999
6,413,942 Methods of delivering a physiologically active polypeptide to a mammal 38 1999
6,706,694 Expression of exogenous polynucleotide sequences in a vertebrate 9 2000
7,250,404 Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response 9 2002
 
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (9)
8,067,383 Synthetic genes and genetic constructs comprising same I 2 2003
7,754,697 Control of gene expression 10 2003
8,048,670 Synthetic genes and genetic constructs 4 2004
7,855,071 Synthetic genes and genetic constructs 0 2004
8,053,419 Synthetic genes and genetic constructs 4 2004
8,183,217 Methods and means for obtaining modified phenotypes 5 2005
8,168,774 Control of gene expression 4 2005
8,431,547 Synthetic genes and genetic constructs 0 2011
8,334,374 Methods and means for obtaining modified phenotypes 0 2012
 
GEN-PROBE INCORPORATED (5)
5,733,781 Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus 2 1994
5,629,413 Oligonucleotides with activity against human immunodeficiency virus 13 1994
5,739,309 Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens 20 1995
5,919,701 Oligonucleotides with activity against human immunodeficiency virus 13 1997
5,874,281 Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens 2 1997
 
IDERA PHARMACEUTICALS, INC. (5)
5,739,308 Integrated oligonucleotides 11 1995
5,929,226 Antisense oligonucleotide alkylphosphonothioates and arylphospohonothioates 27 1995
5,750,674 Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced 2 1995
5,693,773 Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines 35 1995
6,117,993 Synthons for oligonucleotide synthesis 2 1998
 
DAIICHI SANKYO COMPANY, LIMITED (4)
7,335,765 Nucleoside and oligonucleotide analogues 5 2001
7,217,805 Bicyclonucleoside analogues 10 2002
7,314,923 Nucleoside and oligonucleotide analogues 10 2003
7,816,333 Oligonucleotide analogues and methods utilizing the same 1 2007
 
MASSACHUSETTS WORCESTER, UNIVERSITY OF (3)
5,637,573 Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions 9 1995
6,683,167 Hybrid oligonucleotide phosphorothioates 18 2001
7,045,609 Hybrid oligonucleotide phosphorothioates 15 2002
 
THE GENERAL HOSPITAL CORPORATION (2)
5,610,050 Methods of preventing viral replication 2 1993
6,001,990 Antisense inhibition of hepatitis C virus 13 1995
 
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (2)
5,177,198 Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates 58 1989
5,455,233 Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates 113 1992
 
VICAL INCORPORATED (2)
6,867,195 Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected 9 1995
6,214,804 Induction of a protective immune response in a mammal by injecting a DNA sequence 154 1995
 
WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY, THE, A CORP. OF MASSACHUSETTS (2)
4,806,463 Inhibition of HTLV-III by exogenous oligonucleotides 211 1986
5,194,428 Inhibition of influenza virus replication by oligonucleotide phosphorothioates 130 1990
 
BRISTOL-MYERS SQUIBB COMPANY (1)
5,837,852 Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease 5 1993
 
DUKE UNIVERSITY (1)
7,449,449 Particle-mediated transformation of vertebrate tissue cells 0 2003
 
E. I. DU PONT DE NEMOURS AND COMPANY (1)
7,358,234 Induction of a protective immune response through microprojectiles coated with a DNA sequence encoding an immunogenic protein 0 2003
 
EPICLONE, INC. (1)
6,015,676 Method for knocking out gene transcripts by covalently binding of an anti-sense probe 5 1998
 
HOECHST AKTIENGESELLSCHAFT (1)
6,033,909 Oligonucleotide analogs, their preparation and use 16 1994
 
HYBRIDON, INC. (1)
6,346,614 Hybrid oligonucleotide phosphorothioates 45 2000
 
MERCK & CO., INC. (1)
6,995,008 Coordinate in vivo gene expression 1 1999
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
5,474,935 Adeno-associated virus (AAV)-based eucaryotic vectors 91 1993
 
NOVA PHARMACEUTICAL CORPORATION (1)
5,135,917 Interleukin receptor expression inhibiting antisense oligonucleotides 96 1990
 
QIK TECHNOLOGIES, INC. (1)
6,306,831 Transplacental delivery of oligonucleotides 1 1998
 
QUANTITATIVE INFORMATIONAL KNOCKOUT TECHNOLOGY (1)
6,576,218 Transplacental delivery of oligonucleotides 0 2001
 
SCHERING CORPORATION (1)
5,004,810 Antiviral oligomers 100 1988
 
SYNTHETIC GENETICS, INC., A CORP. OF CA (1)
4,904,582 Novel amphiphilic nucleic acid conjugates 135 1987
 
TAKESHI IMANISHI (1)
7,994,145 Bicyclonucleoside analogues 0 2007
 
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
5,098,890 Antisence oligonucleotides to c-myb proto-oncogene and uses thereof 133 1989
 
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (1)
5,942,389 Genes and genetic elements associated with sensitivity to cisplatin 3 1995
 
THE JOHNS HOPKINS UNIVERSITY (1)
5,834,185 Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs, triple helix complexes formed thereby and oligomers used in their formation 12 1994
 
THE PENN STATE RESEARCH FOUNDATION (1)
7,704,965 Methods and materials for treating human papillomavirus infections 0 2003
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
6,806,084 Methods for compositions for in vivo gene delivery 0 1998
 
TRANSPROBE, INC., A CA CORP. (1)
6,521,601 Method and composition for inhibition of viral replication 2 1992
 
WORCESTER FOUNDATION FOR BIOMEDICAL RESEARCH, INC. (1)
6,143,881 Hybrid oligonucleotide phosphorothioates 42 1995
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (1)
5,885,834 Antisense oligodeoxynucleotide against phosphodiesterase 13 1997